Although CD22 has demonstrated efficacy as a target for B-cell acute lymphoblastic leukemia (B-ALL), with over 100 clinical studies conducted either as a single target or in combination with other targets, no therapies targeting CD22 have yet been approved for the treatment of large B-cell lymphoma (LBCL). The gene discussed is CD22; the disease is B-cell acute lymphoblastic leukemia.